

SCOLR Pharma, Inc.  
Form 8-K  
October 14, 2005

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**

---

**Form 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d) OF**  
**THE SECURITIES EXCHANGE ACT OF 1934**

Date of report (date of earliest event reported):

October 12, 2005

**SCOLR Pharma, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
  
incorporation)

**001-31982**  
(Commission File No.)

**91-1689591**  
(I.R.S. Employer  
  
Identification No.)

**3625 132nd Avenue SE**

**Bellevue, WA 98006**

(Address of principal executive offices)

Edgar Filing: SCOLR Pharma, Inc. - Form 8-K

(425) 373-0171

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into a Material Definitive Agreement.**

SCOLR Pharma, Inc. entered into a First Amendment to Lease, effective as of October 12, 2005, to expand its corporate office space by adding 4,125 square feet of administrative space at its existing corporate office building in Bellevue, Washington. The total square footage covered under the lease will increase from 10,510 square feet to 14,635 square feet, and the average annual rent under the lease will increase from \$112,369 to \$174,378. The termination date of the lease remains September 30, 2008.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SCOLR PHARMA, INC.**

Dated: October 14, 2005

By: /s/ Daniel O. Wilds  
Daniel O. Wilds

President and Chief Executive Officer